KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.

Bhavana Pothuri, Sileny Han, Dana M Chase, Florian Heitz, Robert A Burger, Lydia Gaba, Linda Van Le, Eva Guerra, David Bender, Jacob Korach, Noelle Cloven, Cristina Churruca, Philippe Follana, Paul DiSilvestro, Jean-François Baurain, Kris Jardon, Carmela Pisano, Ulla Peen, Johanna Mäenpää, Divya Gupta, Emeline Bacqué, Yong Li, Natalie Compton, Jenya Antonova, Bradley J Monk, Antonio González-Martín

Gynecol Oncol 184 168-177

PMID38325276
PMCID-
DOI10.1016/j.ygyno.2024.01.021
发表日期2024-02-07
入排依据:The record is an original result report from a Phase III randomized trial with a drug intervention, but it focuses on quality-of-life outcomes as a secondary endpoint, not a time-to-event efficacy endpoint required for inclusion.
摘要

摘要

OBJECTIVE: To assess patient-reported health-related quality of life (HRQoL) in patients with ovarian cancer (OC) who received niraparib as first-line maintenance therapy. METHODS: PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) enrolled patients with newly diagnosed advanced OC who responded to first-line platinum-based chemotherapy. Patients were randomized (2:1) to niraparib or placebo once daily in 28-day cycles until disease progression, intolerable toxicity, or death. HRQoL was assessed as a prespecified secondary end point using patient-reported responses to the European Organisation for Research and Treatment of Cancer QOL Questionnaire (EORTC QLQ-C30), the EORTC QLQ Ovarian Cancer Module (EORTC QLQ-OV28), the Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI), and EQ-5D-5L questionnaires. Assessments were collected at baseline and every 8 weeks (±7 days) for 56 weeks, beginning on cycle 1/day 1, then every 12 weeks (±7 days) thereafter while the patient received study treatment. RESULTS: Among trial participants (niraparib, n = 487; placebo, n = 246), PRO adherence exceeded 80% for all instruments across all cycles. Patients reported no decline over time in HRQoL measured via EORTC QLQ-C30 Global Health Status/QoL and FOSI overall scores. Scores for abdominal/gastrointestinal symptoms (EORTC QLQ-OV28) and nausea and vomiting, appetite loss, and constipation (EORTC QLQ-C30) were higher (worse symptoms) in niraparib-treated patients than placebo-treated patients; except for constipation, these differences resolved over time. Patients did not self-report any worsening from baseline of fatigue, headache, insomnia, or abdominal pain on questionnaires. CONCLUSIONS: Despite some early, largely transient increases in gastrointestinal symptoms, patients with OC treated with niraparib first-line maintenance therapy reported no worsening in overall HRQoL.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。